Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079121 | 1.00 | LPAR1 (0.57) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL14721362 | 0.86 | ALDH1A1 (0.52) | MAPTNPC1RAB9APOLBMEN1 | |
| SCHEMBL29475122 | 0.86 | LPAR1 (0.57) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL3504431 | 0.86 | LPAR1 (0.57) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL21198563 | 0.83 | LPAR1 (0.61) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL30823737 | 0.83 | LPAR1 (0.61) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL19643985 | 0.82 | LPAR1 (0.60) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL21217705 | 0.82 | HTT (0.72) | LPAR1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL31630583 | 0.82 | LPAR1 (0.53) | LPAR1MAPTNPC1RAB9APOLB | |
| SCHEMBL1238843 | 0.81 | CYP1A2 (0.54) | LPAR1MAPTNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| EP-1362041-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | Cerep (FR) | 2003-11-19 | — | — | EP | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002068399-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | CEREP (FR) | 2002-09-06 | — | — | WO | disclosed |
| EP-1114052-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017202-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | LPAR1 2691/4885MAPT 2077/4885NPC1 1943/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | LPAR1 2691/4885MAPT 2077/4885NPC1 1943/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | LPAR1 4357/4885MAPT 2881/4885NPC1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.